Bio Voyager

Biotechnology From Bench News

ACT Announces First Patients Undergo Embryonic Stem Cell Transplantation Treatment for Stargardt's Disease and Macular ...Thursday, July 14, 2011 @ 10:10AMMARLBOROUGH, Mass., July 14, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human ...

Combination therapy shows promise against HER2-positive metastatic breast cancerMonday, July 11, 2011 @ 1:48AMAdding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers at The University of Texas MD Anderson Cancer Center and published in the Journal of Clinical Oncology.

Health care: Biotech synergies may change landscapeSunday, July 10, 2011 @ 1:19AMIn a modest office on the eighth floor of the Chase building, Emma Schwartz is shaping El Paso's future.

Reagan v. Freud, science v. religion, population and IslamFriday, July 8, 2011 @ 8:53AMThere’s much to be learned from detective stories, including that the solution to any mystery usually lies in finding the right question to ask.

UNR might hold part of key to treating muscular dystrophyWednesday, July 6, 2011 @ 5:07PMDr. Dean Burkin stands in his Pharmacology lab at the University of Nevada, Reno. Burkin and his students have isolated a protein that protects muscle tissue from muscular dystrophy.